gamma-aminobutyric acid has been researched along with Affective Disorders in 79 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "There is insufficient evidence to support the effectiveness of gabapentin in the treatment of tinnitus." | 9.12 | Treatment of tinnitus with gabapentin: a pilot study. ( Hannley, MT; Stinnet, S; Tucci, DL; Witsell, DL, 2007) |
| "To evaluate the effectiveness of gabapentin (Neurontin) improve the disease-specific quality of life in patients with moderate tinnitus." | 9.12 | Treatment of tinnitus with gabapentin: a pilot study. ( Hannley, MT; Stinnet, S; Tucci, DL; Witsell, DL, 2007) |
| "This study was designed to assess the efficacy and safety of pregabalin-a novel alpha(2)-delta ligand with analgesic, anxiolytic, and anticonvulsant activity-for treating neuropathic pain in patients with post-herpetic neuralgia (PHN)." | 9.11 | Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. ( Cherry, DA; Gálvez, R; Jacquot, F; Maisonobe, P; Sabatowski, R; Versavel, M; Vincent, E, 2004) |
| " Results of a clinical open trial with pivagabine (4-[(2,2-dimethyl-1-oxopropyl) amino]butanoic acid, CAS 69542-93-4, Tonerg) on 22 young patients affected by dysthymic disorders and on 38 older patients affected by adjustment disorders following different stressors (mourning, retirement and recovery in institutions of assistance) are reported." | 9.08 | Clinical evaluation of the efficacy of pivagabine in the treatment of mood and adjustment disorders. ( Gilotta, SM; Luca, S; Terranova, R, 1997) |
| "The efficacy of a new drug, pivagabine (4-[(2,2-dimethyl-1-oxopropyl)amino]butanoic acid, CAS 69542-93-4, Tonerg), was studied on 100 patients affected by insomnia, associated with mood disorders." | 9.08 | Evaluation of the efficacy of pivagabine on insomnia associated with mood disorders. ( Negri, L, 1997) |
| "To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine." | 8.81 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| "Pharmacological evidence suggests the involvement of gamma-aminobutyric acid (GABA) perturbation in the etiology of mood disorders." | 7.72 | Evidence of association between gamma-aminobutyric acid type A receptor genes located on 5q34 and female patients with mood disorders. ( Iwayama-Shigeno, Y; Watanabe, A; Yamada, K; Yoshikawa, T, 2003) |
| "Gabapentin appears to be somewhat effective as add-on treatment in a subgroup of patients with mood disorders in a naturalistic setting." | 7.70 | Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998) |
| "Gabapentin was moderately to markedly effective in 30% (15/50) of patients, with statistically nonsignificant differences between patients with bipolar disorder type I, bipolar disorder type II and NOS, and unipolar major depressive disorder." | 7.70 | Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998) |
| "All charts of patients meeting DSM-IV criteria for bipolar disorder or unipolar major depressive disorder treated with gabapentin in a private psychiatric practice were reviewed and clinical response was assessed retrospectively using the Clinical Global Impressions scale for Improvement (CGI-I)." | 7.70 | Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998) |
| "To determine if gabapentin is effective either as adjunctive treatment or as monotherapy for major affective disorders in a naturalistic setting." | 7.70 | Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998) |
| "Low levels of gamma-aminobutyric acid (GABA) in plasma have been associated with the presence of mood disorders in patients with major depressive disorder." | 7.69 | Plasma levels of gamma-aminobutyric acid and panic disorder. ( Davis, LL; Germine, M; Goddard, AW; Kramer, GL; Narayan, M; Petty, F; Woods, SW, 1996) |
| " Since the effects of carbamazepine on substance P content are identical with previously described effects of lithium, an alteration in substance P neurotransmission may be one of the neurochemical bases of common clinical and behavioral effects of carbamazepine and lithium on affective disorders." | 7.67 | Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: a possible implication of substance P in affective disorders. ( Mataga, N; Mitsushio, H; Takashima, M; Toru, M, 1988) |
| "Pregabalin efficaciously treated the neuropathic pain of PHN." | 6.71 | Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. ( Cherry, DA; Gálvez, R; Jacquot, F; Maisonobe, P; Sabatowski, R; Versavel, M; Vincent, E, 2004) |
| " A slow upward dose titration is recommended to reduce the incidence of serious rash, but this may delay the attainment of adequate dosage for 6 weeks." | 6.41 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| "Lamotrigine has positive effects on cognitive function, but occasionally produces insomnia." | 6.41 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| "Abnormalities of GABAergic (gamma-aminobutyric acidergic) systems may play a role in schizophrenia and mood disorders." | 5.41 | Medial Frontal Cortex GABA Concentrations in Psychosis Spectrum and Mood Disorders: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies. ( Simmonite, M; Steeby, CJ; Taylor, SF, 2023) |
| "Gabapentin was moderately to markedly effective in 30% (15/50) of patients, with statistically nonsignificant differences between patients with bipolar disorder type I, bipolar disorder type II and NOS, and unipolar major depressive disorder." | 5.30 | Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998) |
| "To assess the roles of substance P in neurologic or psychiatric illnesses, effects of acute or chronic (40- or 80-day dietary) treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content were investigated in the rat brain." | 5.27 | Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: a possible implication of substance P in affective disorders. ( Mataga, N; Mitsushio, H; Takashima, M; Toru, M, 1988) |
| "The aims of the present study were to investigate the main demographic and clinical characteristics, comorbidity patterns, use in association and tolerability of pregabalin in a sample of patients with affective disorders, and to compare demographic and clinical variables of the groups divided, according to the treatment pregabalin was associated with." | 5.16 | Tolerability and use in co-administration of pregabalin in affective patients: a 6-month prospective naturalistic study. ( Altamura, AC; Arici, C; Buoli, M; Camuri, G; Dell'Osso, B; Dobrea, C, 2012) |
| "One hundred and fourteen consecutive outpatients, with anxiety and/or depressive disorders with or without comorbidity, were started on pregabalin, assessed and interviewed and their demographic data, associated therapy, tolerability and side effects collected over an observational period of 6 months." | 5.16 | Tolerability and use in co-administration of pregabalin in affective patients: a 6-month prospective naturalistic study. ( Altamura, AC; Arici, C; Buoli, M; Camuri, G; Dell'Osso, B; Dobrea, C, 2012) |
| "To evaluate the effectiveness of gabapentin (Neurontin) improve the disease-specific quality of life in patients with moderate tinnitus." | 5.12 | Treatment of tinnitus with gabapentin: a pilot study. ( Hannley, MT; Stinnet, S; Tucci, DL; Witsell, DL, 2007) |
| "There is insufficient evidence to support the effectiveness of gabapentin in the treatment of tinnitus." | 5.12 | Treatment of tinnitus with gabapentin: a pilot study. ( Hannley, MT; Stinnet, S; Tucci, DL; Witsell, DL, 2007) |
| "This study was designed to assess the efficacy and safety of pregabalin-a novel alpha(2)-delta ligand with analgesic, anxiolytic, and anticonvulsant activity-for treating neuropathic pain in patients with post-herpetic neuralgia (PHN)." | 5.11 | Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. ( Cherry, DA; Gálvez, R; Jacquot, F; Maisonobe, P; Sabatowski, R; Versavel, M; Vincent, E, 2004) |
| " We tested this hypothesis by reviewing the multiple mechanisms of action of topiramate (TPM) and levetiracetam (LEV) together with clinical behavioral side effects of patients who had been treated with TPM and LEV in a tertiary referral center for epilepsy." | 5.11 | Ketter's hypothesis of the mood effects of antiepileptic drugs coupled to the mechanism of action of topiramate and levetiracetam. ( Aldenkamp, AP; Bootsma, HP; Kessels, AG; Leenen, LA; Leonard, BE; Majoie, HJ; Roberts, GM, 2005) |
| " Results of a clinical open trial with pivagabine (4-[(2,2-dimethyl-1-oxopropyl) amino]butanoic acid, CAS 69542-93-4, Tonerg) on 22 young patients affected by dysthymic disorders and on 38 older patients affected by adjustment disorders following different stressors (mourning, retirement and recovery in institutions of assistance) are reported." | 5.08 | Clinical evaluation of the efficacy of pivagabine in the treatment of mood and adjustment disorders. ( Gilotta, SM; Luca, S; Terranova, R, 1997) |
| "The efficacy of a new drug, pivagabine (4-[(2,2-dimethyl-1-oxopropyl)amino]butanoic acid, CAS 69542-93-4, Tonerg), was studied on 100 patients affected by insomnia, associated with mood disorders." | 5.08 | Evaluation of the efficacy of pivagabine on insomnia associated with mood disorders. ( Negri, L, 1997) |
| "To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine." | 4.81 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| "Considerable evidence implicates the neurotransmitter gamma-aminobutyric acid (GABA) in the biochemical pathophysiology of mood disorders." | 4.79 | GABA and mood disorders: a brief review and hypothesis. ( Petty, F, 1995) |
| " This protocol was validated by determining the postmortem cerebrospinal fluid (CSF) glutamic acid (Glu) and γ-aminobutyric acid (GABA) levels of 8 major depressive disorder (MDD) patients, 9 bipolar disorder (BD) patients, and 19 well-matched controls, while also testing the plasma and CSF AA levels of living MDD patients." | 3.83 | A sensitive and practical RP-HPLC-FLD for determination of the low neuroactive amino acid levels in body fluids and its application in depression. ( Bao, AM; Wu, JL; Wu, SH; Yu, SY, 2016) |
| " We investigated the gamma-aminobutyric acid A (GABA(A)) delta receptor subunit gene, GABRD, as a susceptibility gene to childhood-onset mood disorders (COMD) because of substantial evidence implicating GABAergic dysfunction in mood disorders and the position of this gene near the 1p36 linkage region." | 3.76 | Association of the GABRD gene and childhood-onset mood disorders. ( Baji, I; Barr, CL; Benák, I; Besnyo, M; Daróczi, G; Dombovári, E; Feng, Y; Gádoros, J; Kaczvinszk, E; Kapornai, K; Kennedy, JL; Kiss, E; Kothencné, VO; Kovacs, M; Mayer, L; Székely, J; Tamás, Z; Vetró, A, 2010) |
| "Pharmacological evidence suggests the involvement of gamma-aminobutyric acid (GABA) perturbation in the etiology of mood disorders." | 3.72 | Evidence of association between gamma-aminobutyric acid type A receptor genes located on 5q34 and female patients with mood disorders. ( Iwayama-Shigeno, Y; Watanabe, A; Yamada, K; Yoshikawa, T, 2003) |
| "Gabapentin is an anticonvulsant agent, also effective in the treatment of mood disorders and anxiety disorders." | 3.71 | Treatment of alcohol withdrawal with gabapentin. ( Bozikas, V; Gamvrula, K; Karavatos, A; Petrikis, P; Savvidou, I, 2002) |
| "Considerable evidence implicates the neurotransmitter gamma-aminobutyric acid (GABA) in the biochemical pathophysiology of mood disorders." | 3.70 | GABAA alpha-1 subunit gene not associated with depressive symptomatology in mood disorders. ( Catalano, M; Cusin, C; Di Bella, D; Lattuada, E; Lilli, R; Macciardi, F; Serretti, A; Smeraldi, E, 1998) |
| "Gabapentin appears to be somewhat effective as add-on treatment in a subgroup of patients with mood disorders in a naturalistic setting." | 3.70 | Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998) |
| "Gabapentin was moderately to markedly effective in 30% (15/50) of patients, with statistically nonsignificant differences between patients with bipolar disorder type I, bipolar disorder type II and NOS, and unipolar major depressive disorder." | 3.70 | Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998) |
| "All charts of patients meeting DSM-IV criteria for bipolar disorder or unipolar major depressive disorder treated with gabapentin in a private psychiatric practice were reviewed and clinical response was assessed retrospectively using the Clinical Global Impressions scale for Improvement (CGI-I)." | 3.70 | Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998) |
| "To determine if gabapentin is effective either as adjunctive treatment or as monotherapy for major affective disorders in a naturalistic setting." | 3.70 | Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998) |
| "Low levels of gamma-aminobutyric acid (GABA) in plasma have been associated with the presence of mood disorders in patients with major depressive disorder." | 3.69 | Plasma levels of gamma-aminobutyric acid and panic disorder. ( Davis, LL; Germine, M; Goddard, AW; Kramer, GL; Narayan, M; Petty, F; Woods, SW, 1996) |
| " Since the effects of carbamazepine on substance P content are identical with previously described effects of lithium, an alteration in substance P neurotransmission may be one of the neurochemical bases of common clinical and behavioral effects of carbamazepine and lithium on affective disorders." | 3.67 | Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: a possible implication of substance P in affective disorders. ( Mataga, N; Mitsushio, H; Takashima, M; Toru, M, 1988) |
| "Pregabalin efficaciously treated the neuropathic pain of PHN." | 2.71 | Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. ( Cherry, DA; Gálvez, R; Jacquot, F; Maisonobe, P; Sabatowski, R; Versavel, M; Vincent, E, 2004) |
| "In DSM-5, catatonia syndrome may be diagnosed as a specifier to major mood disorders, psychotic disorders, general medical conditions, and as catatonia not otherwise specified." | 2.53 | Catatonia. ( Strik, W; Walther, S, 2016) |
| "Catatonia is potentially life threatening." | 2.53 | Catatonia. ( Strik, W; Walther, S, 2016) |
| " Preclinical studies demonstrate that GABA modulating agents are active in commonly used rodent behavioral models of antidepressant activity, and that chronic administration of antidepressant drugs induces marked changes in GABAergic function." | 2.44 | GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. ( Sanacora, G; Saricicek, A, 2007) |
| "Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter present almost exclusively in the central nervous system (CNS), distributed across almost all brain regions, and expressed in interneurons modulating local circuits." | 2.42 | GABAergic dysfunction in mood disorders. ( Barale, F; Brambilla, P; Perez, J; Schettini, G; Soares, JC, 2003) |
| "The incidence of melanoma is rising rapidly, and the use of this regimen is becoming increasingly common." | 2.41 | Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. ( Everett, JR; Gadd, MA; Greenberg, DB; Haluska, FG; Jonasch, E; Mihm, MA; Ott, M; Ryan, BF; Sober, AJ; Tanabe, KK, 2000) |
| "Lamotrigine has positive effects on cognitive function, but occasionally produces insomnia." | 2.41 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| " A slow upward dose titration is recommended to reduce the incidence of serious rash, but this may delay the attainment of adequate dosage for 6 weeks." | 2.41 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| " Neurochemically, decreased 5-HT uptake in the platelet, increased 5-HT2 receptor in the platelet and cortex of suicides, increased beta receptor in the brains of suicide, functional abnormality of alpha 2 receptor in clonidine, DMI test, GABAB receptor up-regulation after chronic administration of antidepressants and mood stabilizers, participation of neuropeptide Y, and abnormality of HPA axis were recognized." | 2.39 | [Etiology of affective disorders]. ( Kariya, T; Shinohara, M, 1994) |
| "Gabapentin is an anticonvulsant agent, also effective in the treatment of mood disorders and anxiety disorders." | 1.31 | Treatment of alcohol withdrawal with gabapentin. ( Bozikas, V; Gamvrula, K; Karavatos, A; Petrikis, P; Savvidou, I, 2002) |
| "Gabapentin was moderately to markedly effective in 30% (15/50) of patients, with statistically nonsignificant differences between patients with bipolar disorder type I, bipolar disorder type II and NOS, and unipolar major depressive disorder." | 1.30 | Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998) |
| "To assess the roles of substance P in neurologic or psychiatric illnesses, effects of acute or chronic (40- or 80-day dietary) treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content were investigated in the rat brain." | 1.27 | Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: a possible implication of substance P in affective disorders. ( Mataga, N; Mitsushio, H; Takashima, M; Toru, M, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (12.66) | 18.7374 |
| 1990's | 16 (20.25) | 18.2507 |
| 2000's | 28 (35.44) | 29.6817 |
| 2010's | 21 (26.58) | 24.3611 |
| 2020's | 4 (5.06) | 2.80 |
| Authors | Studies |
|---|---|
| Simmonite, M | 1 |
| Steeby, CJ | 1 |
| Taylor, SF | 2 |
| Reddy-Thootkur, M | 1 |
| Kraguljac, NV | 1 |
| Lahti, AC | 1 |
| Felice, D | 1 |
| Cryan, JF | 1 |
| O'Leary, OF | 1 |
| Sbrini, G | 1 |
| Brivio, P | 1 |
| Bosch, K | 1 |
| Homberg, JR | 1 |
| Calabrese, F | 1 |
| Wilkinson, ST | 1 |
| Sanacora, G | 6 |
| Wilczyńska, K | 1 |
| Simonienko, K | 1 |
| Konarzewska, B | 1 |
| Szajda, SD | 1 |
| Waszkiewicz, N | 1 |
| Demeter, E | 1 |
| Phan, KL | 1 |
| Tso, IF | 1 |
| Welsh, RC | 1 |
| Stan, AD | 1 |
| Schirda, CV | 1 |
| Bertocci, MA | 1 |
| Bebko, GM | 1 |
| Kronhaus, DM | 1 |
| Aslam, HA | 1 |
| LaBarbara, EJ | 1 |
| Tanase, C | 1 |
| Lockovich, JC | 1 |
| Pollock, MH | 1 |
| Stiffler, RS | 1 |
| Phillips, ML | 1 |
| Paknejad, B | 1 |
| Kebriaeezadeh, A | 1 |
| Ghahremani, MH | 1 |
| Gharghabi, M | 1 |
| Ostad, SN | 1 |
| Kalia, M | 1 |
| Costa E Silva, J | 1 |
| Bogan, RK | 1 |
| Lee, DO | 1 |
| Buchfuhrer, MJ | 1 |
| Jaros, MJ | 1 |
| Kim, R | 1 |
| Shang, G | 1 |
| Kim, S | 1 |
| Hwang, Y | 1 |
| Webster, MJ | 1 |
| Lee, D | 1 |
| Hantsoo, L | 1 |
| Epperson, CN | 2 |
| Wu, JL | 1 |
| Yu, SY | 1 |
| Wu, SH | 1 |
| Bao, AM | 1 |
| Greenberg, GD | 1 |
| Crabbe, JC | 1 |
| Walther, S | 1 |
| Strik, W | 1 |
| Hamada, Y | 1 |
| Yamashita, A | 1 |
| Tamura, H | 1 |
| Narita, M | 2 |
| Kuzumaki, N | 1 |
| Sümegi, A | 1 |
| Pinna, G | 1 |
| Costa, E | 1 |
| Guidotti, A | 1 |
| Lee, CH | 1 |
| Hwang, IK | 1 |
| Choi, JH | 1 |
| Yoo, KY | 1 |
| Han, TH | 1 |
| Park, OK | 1 |
| Lee, SY | 1 |
| Ryu, PD | 1 |
| Won, MH | 1 |
| Moore, AR | 1 |
| Straube, S | 1 |
| Paine, J | 1 |
| Phillips, CJ | 1 |
| Derry, S | 1 |
| McQuay, HJ | 1 |
| Feng, Y | 1 |
| Kapornai, K | 1 |
| Kiss, E | 1 |
| Tamás, Z | 1 |
| Mayer, L | 1 |
| Baji, I | 1 |
| Daróczi, G | 1 |
| Benák, I | 1 |
| Kothencné, VO | 1 |
| Dombovári, E | 1 |
| Kaczvinszk, E | 1 |
| Besnyo, M | 1 |
| Gádoros, J | 1 |
| Székely, J | 1 |
| Kovacs, M | 1 |
| Vetró, A | 1 |
| Kennedy, JL | 1 |
| Barr, CL | 1 |
| Sibille, E | 1 |
| Morris, HM | 1 |
| Kota, RS | 1 |
| Lewis, DA | 1 |
| Treccani, G | 1 |
| Popoli, M | 1 |
| Mease, PJ | 1 |
| Dundon, K | 1 |
| Sarzi-Puttini, P | 1 |
| Femenía, T | 1 |
| Gómez-Galán, M | 1 |
| Lindskog, M | 1 |
| Magara, S | 1 |
| Dobrea, C | 1 |
| Buoli, M | 1 |
| Arici, C | 1 |
| Camuri, G | 1 |
| Dell'Osso, B | 1 |
| Altamura, AC | 1 |
| Drabkin, R | 1 |
| Calhoun, L | 1 |
| Chang, L | 1 |
| Cloak, CC | 1 |
| Ernst, T | 1 |
| Taylor, M | 1 |
| Bhagwagar, Z | 1 |
| Cowen, PJ | 1 |
| Sharp, T | 1 |
| Brambilla, P | 1 |
| Perez, J | 1 |
| Barale, F | 1 |
| Schettini, G | 1 |
| Soares, JC | 1 |
| Yamada, K | 1 |
| Watanabe, A | 1 |
| Iwayama-Shigeno, Y | 1 |
| Yoshikawa, T | 1 |
| Joffe, H | 1 |
| Soares, CN | 1 |
| Cohen, LS | 1 |
| Rothman, DL | 1 |
| Mason, G | 1 |
| Krystal, JH | 3 |
| Sabatowski, R | 1 |
| Gálvez, R | 1 |
| Cherry, DA | 1 |
| Jacquot, F | 1 |
| Vincent, E | 1 |
| Maisonobe, P | 1 |
| Versavel, M | 1 |
| Kendell, SF | 1 |
| Roberts, GM | 1 |
| Majoie, HJ | 1 |
| Leenen, LA | 1 |
| Bootsma, HP | 1 |
| Kessels, AG | 1 |
| Aldenkamp, AP | 1 |
| Leonard, BE | 1 |
| Van Den Bogaert, A | 1 |
| Del-Favero, J | 1 |
| Van Broeckhoven, C | 1 |
| Witsell, DL | 1 |
| Hannley, MT | 1 |
| Stinnet, S | 1 |
| Tucci, DL | 1 |
| Victorri-Vigneau, C | 1 |
| Guerlais, M | 1 |
| Jolliet, P | 1 |
| Bielau, H | 1 |
| Steiner, J | 1 |
| Mawrin, C | 1 |
| Trübner, K | 1 |
| Brisch, R | 1 |
| Meyer-Lotz, G | 1 |
| Brodhun, M | 1 |
| Dobrowolny, H | 1 |
| Baumann, B | 1 |
| Gos, T | 1 |
| Bernstein, HG | 1 |
| Bogerts, B | 1 |
| Saricicek, A | 1 |
| Savica, R | 1 |
| Beghi, E | 1 |
| Mazzaglia, G | 1 |
| Innocenti, F | 1 |
| Brignoli, O | 1 |
| Cricelli, C | 1 |
| Caputi, AP | 1 |
| Musolino, R | 1 |
| Spina, E | 1 |
| Trifirò, G | 1 |
| Baillieux, H | 1 |
| Verslegers, W | 1 |
| Paquier, P | 1 |
| De Deyn, PP | 1 |
| Mariën, P | 1 |
| Sheard, MH | 1 |
| Berrettini, WH | 2 |
| Goldin, LR | 1 |
| Nurnberger, JI | 2 |
| Gershon, ES | 2 |
| Hare, TA | 1 |
| Simmons-Alling, S | 1 |
| Post, RM | 3 |
| Emrich, HM | 1 |
| Altmann, H | 1 |
| Dose, M | 1 |
| von Zerssen, D | 1 |
| Shinohara, M | 1 |
| Kariya, T | 2 |
| Petty, F | 5 |
| Goddard, AW | 1 |
| Narayan, M | 1 |
| Woods, SW | 1 |
| Germine, M | 1 |
| Kramer, GL | 4 |
| Davis, LL | 2 |
| Yonkers, KA | 1 |
| Negri, L | 1 |
| Terranova, R | 1 |
| Gilotta, SM | 1 |
| Luca, S | 1 |
| Prosser, J | 1 |
| Hughes, CW | 1 |
| Sheikha, S | 1 |
| Kowatch, RA | 1 |
| Rosenbarger, N | 1 |
| Trent, J | 1 |
| Vaquerizo, J | 1 |
| Romero-Rodríguez, JC | 1 |
| González-Roncero, A | 1 |
| Gómez-Marcos, A | 1 |
| Ghaemi, SN | 1 |
| Katzow, JJ | 1 |
| Desai, SP | 1 |
| Goodwin, FK | 1 |
| Shiah, IS | 1 |
| Yatham, LN | 1 |
| Serretti, A | 1 |
| Macciardi, F | 1 |
| Cusin, C | 1 |
| Lattuada, E | 1 |
| Lilli, R | 1 |
| Di Bella, D | 1 |
| Catalano, M | 1 |
| Smeraldi, E | 1 |
| Fulton, M | 1 |
| Kram, M | 1 |
| Rush, AJ | 2 |
| Greenberg, DB | 1 |
| Jonasch, E | 1 |
| Gadd, MA | 1 |
| Ryan, BF | 1 |
| Everett, JR | 1 |
| Sober, AJ | 1 |
| Mihm, MA | 1 |
| Tanabe, KK | 1 |
| Ott, M | 1 |
| Haluska, FG | 1 |
| Frye, MA | 2 |
| Ketter, TA | 2 |
| Kimbrell, TA | 1 |
| Dunn, RT | 1 |
| Speer, AM | 2 |
| Osuch, EA | 2 |
| Luckenbaugh, DA | 2 |
| Cora-Ocatelli, G | 1 |
| Leverich, GS | 2 |
| Iqbal, MM | 1 |
| Gundlapalli, SP | 1 |
| Ryan, WG | 1 |
| Ryals, T | 1 |
| Passman, TE | 1 |
| Goldberg, JF | 1 |
| Burdick, KE | 1 |
| Megna, JL | 1 |
| Devitt, PJ | 1 |
| Sauro, MD | 1 |
| Dewan, MJ | 1 |
| Obrocea, GV | 1 |
| Dunn, RM | 1 |
| Jajodia, K | 1 |
| Bozikas, V | 1 |
| Petrikis, P | 1 |
| Gamvrula, K | 1 |
| Savvidou, I | 1 |
| Karavatos, A | 1 |
| Hurley, SC | 1 |
| Blumberg, H | 1 |
| Anand, A | 1 |
| Charney, DS | 1 |
| Marek, G | 1 |
| Goddard, A | 1 |
| Mason, GF | 1 |
| Sachs, GS | 1 |
| Cosgrove, VE | 1 |
| Roy, A | 1 |
| DeJong, J | 1 |
| Lamparski, D | 1 |
| George, T | 1 |
| Linnoila, M | 1 |
| Dunnam, D | 1 |
| Ciu, Z | 1 |
| Gao, BL | 1 |
| Mitsushio, H | 1 |
| Takashima, M | 1 |
| Mataga, N | 1 |
| Toru, M | 1 |
| Motohashi, N | 1 |
| Ikawa, K | 1 |
| Lloyd, KG | 1 |
| Morselli, PL | 1 |
| Bartholini, G | 1 |
| Suzdak, PD | 1 |
| Gianutsos, G | 1 |
| Lerer, B | 1 |
| Shapira, B | 1 |
| Waintraub, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Psychophysiology, Neurosteroids, and Stress in Premenstrual Dysphoric Disorder[NCT02777372] | Phase 4 | 84 participants (Actual) | Interventional | 2016-04-01 | Completed | ||
| Cannabidiol for Fibromyalgia -The CANNFIB Trial Protocol for a Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial[NCT04729179] | Phase 3 | 200 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Intramuscular Ketamine Versus Escitalopram and Aripiprazole in Acute and Maintenance Treatment of Patients With Treatment-resistant Depression[NCT04234776] | Phase 4 | 88 participants (Anticipated) | Interventional | 2018-04-03 | Enrolling by invitation | ||
| Efficacy and Safety Analyses of Mirtazapine in the Treatment of Malignant Tumor Related Depression: A Phase II, Placebo-controlled, Randomized, Double-blinded Clinical Trial in Advanced Non-small Cell Lung Cancer Patients[NCT02650544] | Phase 2 | 236 participants (Anticipated) | Interventional | 2015-12-31 | Active, not recruiting | ||
| Remote Effects of Stroke on Cerebral Metabolism. Evaluation With Positron Emission Tomography and Proton Magnetic Resonance Spectroscopy[NCT00063180] | 70 participants | Observational | 2003-06-19 | Completed | |||
| Comparing Therapeutic Efficacy and Cognitive Side Effects of Electroconvulsive Therapy (ECT) Using Ketamine Versus Methohexital Anesthesia[NCT01881763] | Phase 4 | 31 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Use of Single Dose Pre-Operative Pregabalin for Post-Operative Analgesia in Bilateral Head and Neck Cancer Surgery: A Randomized, Double-Blinded, Placebo-Controlled Trial[NCT03714867] | Phase 4 | 0 participants (Actual) | Interventional | 2019-03-22 | Withdrawn (stopped due to Inability to recruit patients) | ||
| Evaluation of Lamotrigine (Lamictal® (Registered Trademark)) Monotherapy and Gabapentin (Neurontin® (Registered Trademark)) Monotherapy in the Treatment of Mood Disorders[NCT00001482] | Phase 2 | 60 participants | Interventional | 1995-05-31 | Completed | ||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Acoustic startle response (ASR) is measured during the follicular and luteal phase of the menstrual cycle in controls and those with PMDD. Magnitude of ASR is measured using the eyeblink reflex, by recording activity from the orbicularis oculi muscle. Recording is performed via two surface disk electrodes (Ag-AgCl) applied underneath the left eye; one in line with the pupil and one 1-2 cm lateral to the first one. For the primary outcome of baseline ASR magnitude over the menstrual cycle, peak amplitude of the blink reflex was determined in the 20-120-ms time frame following stimulus onset relative to baseline (baseline is the average baseline electromyography (EMG) level for the 50 ms immediately preceding auditory stimulus onset). ASR is measured in microvolts, and raw ASR results are standardized to t-scores. Higher ASR t-score indicates greater contraction of the the orbicularis oculi muscle. A t-score of 50 indicates the population mean with a standard deviation of 10. (NCT02777372)
Timeframe: Month 1 (Follicular), Month 2 (Luteal)
| Intervention | t score (Mean) | |
|---|---|---|
| Month 1 (Follicular) | Month 2 (Luteal) | |
| Control | 54.2 | 56.4 |
| Sertraline | 53.7 | 53.3 |
This outcome examines the impact of luteal phase treatment with a selective serotonin reuptake inhibitor (SSRI) (PMDD group only) on acoustic startle response (ASR). ASR is measured using the eyeblink reflex, measured by recording activity from the orbicularis oculi muscle. Recording is performed via two surface disk electrodes (Ag-AgCl) applied underneath the left eye; one in line with the pupil and one 1-2 cm lateral to the first one. Peak amplitude of the blink reflex is determined in the 20-120-ms time frame following stimulus onset. PMDD participants complete test day 3 (Luteal Month 3) while on sertraline and their ASR magnitude will be compared to their previous luteal test day (Luteal Month 2). ASR is measured in microvolts, and raw ASR results are standardized to t-scores. Higher ASR t-score indicates greater contraction of the the orbicularis oculi muscle. A t-score of 50 indicates the population mean with a standard deviation of 10. (NCT02777372)
Timeframe: Month 2 (Luteal), Month 3 (Luteal)
| Intervention | t score (Mean) | |
|---|---|---|
| Month 2 (Luteal) | Month 3 (Luteal) | |
| Control | 56.4 | 51.8 |
| Sertraline | 53.3 | 52.2 |
Blood samples were collected to measure serum interleukin-6 (IL-6). IL-6 levels were compared in the follicular and luteal phases, between Control and PMDD groups. Levels are measured in picogram/milliliter (pg/mL). (NCT02777372)
Timeframe: Month 1 (Follicular ), Month 2 (Luteal )
| Intervention | picogram/milliliter (pg/mL) (Mean) | |
|---|---|---|
| Month 1 (Follicular) | Month 2 (Luteal) | |
| Control | 0.4 | .59 |
| Sertraline | .34 | .4 |
Blood samples were collected to measure serum TNF-alpha levels in the Follicular and Luteal 1 phases. Levels are measured in picogram/milliliter (pg/mL). (NCT02777372)
Timeframe: Month 1 (Follicular ), Month 2 (Luteal )
| Intervention | pg/mL (Mean) | |
|---|---|---|
| Month 1 (Follicular ) | Month 2 (Luteal ) | |
| Control | 1.27 | 1.27 |
| Sertraline | 1.63 | 1.54 |
The items mostly range from a score of 0-4 but there are some questions that range from a score of 0-2. The maximum total score that can be reported is 76 and the lowest score is 0. Higher values represent a worse outcome. Items are summed together to compute the total score. Remission is defined as two consecutive Hamilton Rating Scale for Depression, 24 items (HRSD-24) scores < 10, and HRSD-24 total score does not increase > 3 points on the second consecutive HRSD-24, or remains < 6 at the last two consecutive treatments. HRSD-24 scores are used to define remission. (NCT01881763)
Timeframe: Days required to achieve remission (on average 3-4 weeks)
| Intervention | HRSD units (Mean) |
|---|---|
| Ketamine | 7.82 |
| Methohexital | 8.60 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
37 reviews available for gamma-aminobutyric acid and Affective Disorders
| Article | Year |
|---|---|
Medial Frontal Cortex GABA Concentrations in Psychosis Spectrum and Mood Disorders: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies.
Topics: Frontal Lobe; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Mood Disorders; Proton Magnetic Resona | 2023 |
The role of glutamate and GABA in cognitive dysfunction in schizophrenia and mood disorders - A systematic review of magnetic resonance spectroscopy studies.
Topics: Brain; Cognitive Dysfunction; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Magnetic Resonance Spe | 2022 |
A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems.
Topics: Animals; Antidepressive Agents; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Mood Disorders | 2019 |
Morphological changes of the brain in mood disorders.
Topics: Bipolar Disorder; Brain; gamma-Aminobutyric Acid; Humans; Mood Disorders; Neuroimaging; Neurons | 2018 |
Biomarkers of psychiatric diseases: current status and future prospects.
Topics: Acetyltransferases; Alzheimer Disease; Biomarkers; Bipolar Disorder; Brain; Brain-Derived Neurotroph | 2015 |
Premenstrual Dysphoric Disorder: Epidemiology and Treatment.
Topics: Diagnosis, Differential; Diagnostic and Statistical Manual of Mental Disorders; Disease Management; | 2015 |
Gene Targeting Studies of Hyperexcitability and Affective States of Alcohol Withdrawal in Rodents.
Topics: Alcoholism; Animals; Animals, Genetically Modified; Disease Models, Animal; Epilepsy; gamma-Aminobut | 2016 |
Catatonia.
Topics: Benzodiazepines; Catatonia; Diagnostic and Statistical Manual of Mental Disorders; Electroconvulsive | 2016 |
[Mood stabilizers--past, present and future].
Topics: Affect; Antimanic Agents; Bipolar Disorder; Calcium; Carbamazepine; Depressive Disorder; gamma-Amino | 2008 |
SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake.
Topics: Animals; Brain; Fluoxetine; gamma-Aminobutyric Acid; Humans; Mental Disorders; Mood Disorders; Pregn | 2009 |
Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.
Topics: Animals; Antidepressive Agents; Brain; Drug Evaluation, Preclinical; gamma-Aminobutyric Acid; Glucoc | 2012 |
Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.
Topics: Animals; Antidepressive Agents; Brain; Drug Evaluation, Preclinical; gamma-Aminobutyric Acid; Glucoc | 2012 |
Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.
Topics: Animals; Antidepressive Agents; Brain; Drug Evaluation, Preclinical; gamma-Aminobutyric Acid; Glucoc | 2012 |
Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.
Topics: Animals; Antidepressive Agents; Brain; Drug Evaluation, Preclinical; gamma-Aminobutyric Acid; Glucoc | 2012 |
Pharmacotherapy of fibromyalgia.
Topics: Analgesics; Chronic Pain; Clinical Trials as Topic; Cognition Disorders; Cyclopropanes; Duloxetine H | 2011 |
Dysfunctional hippocampal activity affects emotion and cognition in mood disorders.
Topics: Animals; Antidepressive Agents; Behavioral Symptoms; Cognition Disorders; gamma-Aminobutyric Acid; G | 2012 |
Magnetic resonance spectroscopy studies of GABA in neuropsychiatric disorders.
Topics: Anxiety Disorders; Brain; Brain Chemistry; Creatine; Depressive Disorder; Epilepsy; GABA Agents; gam | 2003 |
GABA and mood disorders.
Topics: Brain; gamma-Aminobutyric Acid; Humans; Limbic System; Magnetic Resonance Spectroscopy; Mood Disorde | 2003 |
GABAergic dysfunction in mood disorders.
Topics: Brain Chemistry; gamma-Aminobutyric Acid; Humans; Mood Disorders | 2003 |
Assessment and treatment of hot flushes and menopausal mood disturbance.
Topics: Acetates; Aging; Amines; Anti-Anxiety Agents; Cognition Disorders; Cyclohexanecarboxylic Acids; Fema | 2003 |
Clinical studies implementing glutamate neurotransmission in mood disorders.
Topics: Animals; Brain Chemistry; Depression; gamma-Aminobutyric Acid; Glutamates; Humans; Magnetic Resonanc | 2003 |
GABA and glutamate systems as therapeutic targets in depression and mood disorders.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Drug Delivery Systems; Excitatory Amino Acid An | 2005 |
Major affective disorders and schizophrenia: a common molecular signature?
Topics: Dopamine; gamma-Aminobutyric Acid; Genetic Predisposition to Disease; Glutamic Acid; Humans; Mood Di | 2006 |
GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action.
Topics: Affect; Animals; Antidepressive Agents; Depressive Disorder; Excitatory Amino Acid Agonists; Excitat | 2007 |
Clinical pharmacology of aggressive behavior.
Topics: Adolescent; Adult; Aged; Aggression; Anger; Anti-Anxiety Agents; Benzodiazepines; Brain Chemistry; C | 1984 |
Genetic factors in affective illness.
Topics: ABO Blood-Group System; Blood Platelets; Cholinergic Fibers; Diseases in Twins; Female; gamma-Aminob | 1984 |
[Etiology of affective disorders].
Topics: Animals; gamma-Aminobutyric Acid; Humans; Mood Disorders; Neuropeptides; Neurosecretory Systems; Neu | 1994 |
GABA and mood disorders: a brief review and hypothesis.
Topics: Biomarkers; Bipolar Disorder; Brain Stem; Depressive Disorder; gamma-Aminobutyric Acid; Hippocampus; | 1995 |
The association between premenstrual dysphoric disorder and other mood disorders.
Topics: Biomarkers; Comorbidity; Depressive Disorder; Diagnosis, Differential; Endorphins; Family; Female; g | 1997 |
GABA function in mood disorders: an update and critical review.
Topics: Animals; Antidepressive Agents; Antimanic Agents; Electroconvulsive Therapy; gamma-Aminobutyric Acid | 1998 |
Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes.
Topics: Acetates; Adult; Amines; Anti-Anxiety Agents; Antimanic Agents; Antineoplastic Agents; Bipolar Disor | 2000 |
Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants.
Topics: Abnormalities, Drug-Induced; Acetates; Adult; Amines; Antimanic Agents; Benzodiazepines; Breast Feed | 2001 |
Cognitive side effects of anticonvulsants.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cognition Disorders; Cyclohexane | 2001 |
Lamotrigine update and its use in mood disorders.
Topics: Acetates; Aggression; Amines; Antidepressive Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; | 2002 |
Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments.
Topics: Antidepressive Agents; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Models, Neurological; Mood Di | 2002 |
Bipolar disorder: current treatments and new strategies.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Fructose; Gabapent | 1998 |
[Significance of GABA-energic system in the central nervous system in clinical psychologic medicine].
Topics: Animals; Brain Chemistry; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Hepatic Encephalopathy; | 1990 |
GABA and affective disorders.
Topics: Animals; Antidepressive Agents; Disease Models, Animal; gamma-Aminobutyric Acid; Humans; Mood Disord | 1987 |
Neurochemical mechanisms of mood stabilization. Focus on electroconvulsive therapy.
Topics: Acetylcholine; Antidepressive Agents; Brain; Choline O-Acetyltransferase; Electroconvulsive Therapy; | 1986 |
[GABA and mood disorders].
Topics: 4-Aminobutyrate Transaminase; Animals; Depression; Disease Models, Animal; gamma-Aminobutyric Acid; | 1987 |
14 trials available for gamma-aminobutyric acid and Affective Disorders
| Article | Year |
|---|---|
Abnormal GABAergic function and negative affect in schizophrenia.
Topics: Adult; Cerebral Cortex; Cross-Over Studies; Female; GABA Modulators; gamma-Aminobutyric Acid; Humans | 2014 |
Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: Pooled analyses from 3 trials of gabapentin enacarbil.
Topics: Adult; Carbamates; Dose-Response Relationship, Drug; Double-Blind Method; Female; gamma-Aminobutyric | 2015 |
Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain.
Topics: Activities of Daily Living; Adult; Analgesics; Fatigue Syndrome, Chronic; Female; Fibromyalgia; gamm | 2010 |
Tolerability and use in co-administration of pregabalin in affective patients: a 6-month prospective naturalistic study.
Topics: Adult; Aged; Anticonvulsants; Antidepressive Agents; Anxiety Disorders; Benzodiazepines; Depressive | 2012 |
Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticonvulsants; Dose-Response Relationship, D | 2004 |
Ketter's hypothesis of the mood effects of antiepileptic drugs coupled to the mechanism of action of topiramate and levetiracetam.
Topics: Adult; Anticonvulsants; Chi-Square Distribution; Demography; Drug Therapy, Combination; Epilepsy; Fe | 2005 |
Treatment of tinnitus with gabapentin: a pilot study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Auditory Threshold; Cyclohexanecarbo | 2007 |
Therapeutic effects of GABA-ergic drugs in affective disorders. A preliminary report.
Topics: Adolescent; Adult; Analgesics; Anticonvulsants; Bipolar Disorder; Carbamazepine; Clinical Trials as | 1983 |
Evaluation of the efficacy of pivagabine on insomnia associated with mood disorders.
Topics: Adult; Blood Pressure; Double-Blind Method; Female; gamma-Aminobutyric Acid; Heart Rate; Humans; Mal | 1997 |
Clinical evaluation of the efficacy of pivagabine in the treatment of mood and adjustment disorders.
Topics: Adjustment Disorders; Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Double-Blind Meth | 1997 |
Plasma GABA in children and adolescents with mood, behavior, and comorbid mood and behavior disorders: a preliminary study.
Topics: Adolescent; Child; Child Behavior Disorders; Female; gamma-Aminobutyric Acid; Humans; Male; Mood Dis | 1997 |
A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders.
Topics: Acetates; Adult; Amines; Antimanic Agents; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-B | 2000 |
Gabapentin's effect on agitation in severely and persistently mentally ill patients.
Topics: Acetates; Amines; Antimanic Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobuty | 2002 |
Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders.
Topics: Acetates; Adult; Aged; Amines; Antidepressive Agents; Cross-Over Studies; Cross-Sectional Studies; C | 2002 |
28 other studies available for gamma-aminobutyric acid and Affective Disorders
| Article | Year |
|---|---|
GABA
Topics: Anxiety; Anxiety Disorders; gamma-Aminobutyric Acid; Humans; Mood Disorders; Receptors, GABA; Recept | 2022 |
Enrichment Environment Positively Influences Depression- and Anxiety-Like Behavior in Serotonin Transporter Knockout Rats through the Modulation of Neuroplasticity, Spine, and GABAergic Markers.
Topics: Animals; Animals, Genetically Modified; Anxiety; Behavior, Animal; Brain; Brain-Derived Neurotrophic | 2020 |
Glutamate and GABA contributions to medial prefrontal cortical activity to emotion: implications for mood disorders.
Topics: Adult; Anger; Emotions; Facial Expression; Fear; Female; gamma-Aminobutyric Acid; Glutamic Acid; Gyr | 2014 |
Gabapentin Enhances Neurogenesis in E14 Rat Embryonic Neocortex Stem Cells.
Topics: Amines; Animals; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cyclohexanecarboxylic Ac | 2015 |
Differential activation of immune/inflammatory response-related co-expression modules in the hippocampus across the major psychiatric disorders.
Topics: Analysis of Variance; Case-Control Studies; Databases, Factual; Female; gamma-Aminobutyric Acid; Gen | 2016 |
A sensitive and practical RP-HPLC-FLD for determination of the low neuroactive amino acid levels in body fluids and its application in depression.
Topics: Aged; Aged, 80 and over; Amino Acids; Bipolar Disorder; Body Fluids; Case-Control Studies; Chromatog | 2016 |
Functional role of cortical astrocytes in sleep/affective dysregulation under the chronic pain: analysis by artificial control of astrocytes using optogenetics.
Topics: Animals; Astrocytes; Chronic Pain; gamma-Aminobutyric Acid; Humans; Mood Disorders; Optogenetics; Sl | 2016 |
Calcium binding proteins immunoreactivity in the rat basolateral amygdala following myocardial infarction.
Topics: Amygdala; Animals; Biomarkers; Brain Mapping; Calbindin 2; Calbindins; Calcium-Binding Proteins; Dep | 2010 |
Association of the GABRD gene and childhood-onset mood disorders.
Topics: Adolescent; Age of Onset; Female; gamma-Aminobutyric Acid; Genotype; Haplotypes; Humans; Hungary; Li | 2010 |
GABA-related transcripts in the dorsolateral prefrontal cortex in mood disorders.
Topics: Adult; Age Factors; Aged; Biomarkers; Bipolar Disorder; Down-Regulation; Female; gamma-Aminobutyric | 2011 |
Anorgasmia and withdrawal syndrome in a woman taking gabapentin.
Topics: Acetates; Adult; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; H | 2003 |
Evidence of association between gamma-aminobutyric acid type A receptor genes located on 5q34 and female patients with mood disorders.
Topics: Adult; Brain; Brain Chemistry; Chromosomes, Human, Pair 5; DNA Mutational Analysis; Female; gamma-Am | 2003 |
Abuse, dependency and withdrawal with gabapentin: a first case report.
Topics: Aged; Alcoholism; Amines; Antimanic Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-A | 2007 |
Dysregulation of GABAergic neurotransmission in mood disorders: a postmortem study.
Topics: Aged; Bipolar Disorder; Brain; Brain Mapping; Female; gamma-Aminobutyric Acid; Gene Expression Regul | 2007 |
Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005.
Topics: Adolescent; Adult; Age Distribution; Aged; Amines; Anticonvulsants; Carbamazepine; Catchment Area, H | 2007 |
Cerebellar cognitive affective syndrome associated with topiramate.
Topics: Amines; Anticonvulsants; Carbamazepine; Cerebellar Diseases; Cerebellum; Cognition Disorders; Cycloh | 2008 |
Reduced plasma and CSF gamma-aminobutyric acid in affective illness: effect of lithium carbonate.
Topics: Adult; Bipolar Disorder; Depressive Disorder; Female; gamma-Aminobutyric Acid; Humans; Lithium; Lith | 1983 |
Plasma levels of gamma-aminobutyric acid and panic disorder.
Topics: Adult; Agoraphobia; Anxiety Disorders; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; M | 1996 |
[Partial complex status epilepticus: diagnostic difficulties].
Topics: Anticonvulsants; Child; Crime; Diagnosis, Differential; Drug Therapy, Combination; Electroencephalog | 1998 |
Gabapentin treatment of mood disorders: a preliminary study.
Topics: Acetates; Adolescent; Adult; Aged; Ambulatory Care; Amines; Anticonvulsants; Antidepressive Agents; | 1998 |
GABAA alpha-1 subunit gene not associated with depressive symptomatology in mood disorders.
Topics: Adult; Anxiety; Bipolar Disorder; Delusions; Depression; DNA; Female; gamma-Aminobutyric Acid; Genet | 1998 |
Evidence for the segregation of a major gene for human plasma GABA levels.
Topics: Adolescent; Adult; Chromosome Segregation; Family Health; Female; gamma-Aminobutyric Acid; Genes, Re | 1999 |
Treatment of alcohol withdrawal with gabapentin.
Topics: Acetates; Adult; Amines; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Ethanol; Gabapentin; gamm | 2002 |
Depression among alcoholics. Relationship to clinical and cerebrospinal fluid variables.
Topics: Adult; Age Factors; Alcohol Drinking; Alcoholism; Anxiety Disorders; Depressive Disorder; Divorce; D | 1991 |
Plasma GABA in mood disorders.
Topics: Affective Disorders, Psychotic; gamma-Aminobutyric Acid; Humans; Mood Disorders | 1990 |
Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: a possible implication of substance P in affective disorders.
Topics: Animals; Body Weight; Brain Chemistry; Carbamazepine; Dopamine; Dose-Response Relationship, Drug; ga | 1988 |
GABAB receptors are up-regulated by chronic treatment with lithium or carbamazepine. GABA hypothesis of affective disorders?
Topics: Animals; Baclofen; Carbamazepine; Cerebral Cortex; gamma-Aminobutyric Acid; Hippocampus; Lithium; Ma | 1989 |
Parallel changes in the sensitivity of gamma-aminobutyric acid and noradrenergic receptors following chronic administration of antidepressant and GABAergic drugs. A possible role in affective disorders.
Topics: Animals; Anticonvulsants; Antidepressive Agents; Baclofen; Cerebral Cortex; Dihydroalprenolol; gamma | 1985 |